Damora GC awarded 250K stock options

Damora Therapeutics, Inc. reported that its General Counsel, Winslow Garrett, received a grant of stock options covering 250,000 shares of common stock.

Rhea-AI Filing Summary

Damora Therapeutics, Inc. reported that its General Counsel, Winslow Garrett, received a grant of stock options covering 250,000 shares of common stock. The options have an exercise price of $23.05 per share and expire on March 23, 2036.

According to the terms, the award will vest 25% on March 23, 2027 and then in equal monthly installments through March 23, 2030, conditioned on continued service. Following this grant, Garrett holds 250,000 stock options directly.

Insider Trade Summary

Grant/Award: 250,000 shares

Grant/Award 1 txn

Insider Winslow Garrett

Role General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	250,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 250,000 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 23, 2027 and in equal monthly installments thereafter through March 23, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Damora Therapeutics (DMRA) disclose for Winslow Garrett?

Damora Therapeutics reported a stock option grant to General Counsel Winslow Garrett for 250,000 underlying common shares. The options were awarded with an exercise price of $23.05 per share and represent a compensation-related acquisition, not an open-market purchase or sale.

What are the key terms of Winslow Garrett’s new Damora Therapeutics (DMRA) stock options?

Garrett’s stock options cover 250,000 Damora common shares at an exercise price of $23.05 per share. They expire on March 23, 2036, providing a long-dated incentive aligned with his role as General Counsel at the company.

How do Winslow Garrett’s Damora Therapeutics (DMRA) options vest over time?

The option award vests 25% on March 23, 2027, with the remaining 75% vesting in equal monthly installments through March 23, 2030. Vesting is contingent on Garrett’s continued service to Damora Therapeutics on each scheduled vesting date.

How many Damora Therapeutics (DMRA) options does Winslow Garrett hold after this grant?

After this award, Winslow Garrett holds 250,000 stock options directly. These options each relate to one share of Damora common stock and reflect his current derivative position as reported, all stemming from this single compensation grant.

Is Winslow Garrett’s Damora Therapeutics (DMRA) transaction a market purchase or sale?

The transaction is a grant of stock options as compensation, not a market trade. It is categorized as an acquisition under a grant or award, with no reported open-market buying or selling of Damora common stock by Garrett in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winslow Garrett

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.,

221 CRESCENT ST, BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$23.05	03/23/2026		A		250,000		(1)	03/23/2036	Common Stock	250,000	$0	250,000	D

Explanation of Responses:

1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest as to 25% on March 23, 2027 and in equal monthly installments thereafter through March 23, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Garrett Winslow	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)